Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Completed · Phase 3

Conditions studied: Gastroesophageal Reflux Disease (GERD)

In brief

The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).

Key facts

Study ID

NCT00839306

Run by

Eisai Inc.

People needed

240

Starts

2008-08-01

Expected to finish

2010-01-01

Last updated by the study team

2016-02-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Associates, Ltd. — Moline, Illinois, United States
• Midwest Clinical — Moline, Illinois, United States
• Research — Moline, Illinois, United States
• Study site — Moline, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.